Open AccessFactor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome
Author(s) -
Benedetto Chiara,
Marozio Luca,
Salton Loredana,
Maulà Vincenza,
Chieppa Giuseppina,
Massobrio Marco
Publication year - 2002
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1034/j.1600-0412.2002.811201.x
Subject(s) - preeclampsia , factor v leiden , hellp syndrome , medicine , factor v , risk factor , odds ratio , gastroenterology , thrombophilia , pregnancy , thrombosis , venous thrombosis , genetics , biology
Background. The association of factor V and factor II mutations with preeclampsia and hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome, and a possible role of the two thrombophilic mutations in the pathogenesis of the diseases have been previously investigated. The results, however, are still inconclusive and contradictory. Methods. A case–control study was performed over an interval of 24 months, on 111 subjects with preeclampsia and 111 normal pregnant women matched for age and parity, without previous thromboembolic disorders. The subjects were tested for the mutation A1691G in the factor V gene (R506Q or Leiden mutation) and the mutation A20210G in the factor II (prothrombin) gene. The Student's t ‐test and the χ 2 ‐test were applied when appropriate, and odds ratios and 95% confidence intervals were calculated. Results. Fourteen patients with preeclampsia (12.6%) had at least one of the two mutations, as compared with six controls (5.4%). Factor V Leiden was found in eight patients with preeclampsia (7.2%) and in five controls (4.5%). Factor II G20210A was detected in eight preeclamptic women (7.2%) and in one normal pregnant woman (0.9%)( p = 0.041). In the subgroup of 32 preeclamptic subjects with HELLP syndrome, factor V Leiden was found in three patients (9.3%) and factor II G20210A in two (6.2%). Conclusions. The prevalence of factor V and factor II mutations is increased in patients with preeclampsia; the thrombophilic mutations may interact with other pathogenic factors to determine the clinical features of the disease and of its complications.